[1]
|
Xia, J.H. and Wu, HS. (1993) Anti-DNA antibodies in SLE pathogenesis significance. Shanghai Journal of Immunology, 13, 172-175.
|
[2]
|
Terman, D.S., Buffaloe, G., Mattioli, C., et al. (1979) Extracorporeal immunoad-sorption: Initial experience in human systemic lupus erythematosus. Lancet, 2, 824-827.
doi:10.1016/S0140-6736(79)92177-9
|
[3]
|
Stummvoll, G.H. (2011) Immunoadsorption (IAS) for sys- temic lupus erythematosus. Lupus February, 20, 115-119.
|
[4]
|
Kihm, L.P. and Schwenger, V. (2011) Plasmapherese und immunadsorption auf der intensivstation. Der Nephrology, 6, 149-154.
|
[5]
|
Kong, D.L., Schuett, W., Boeden, H.F., et al. (2000) Development of a DNA immunoadsorbent: coupling DNA on sepharose 4FF by an efficient activation method. Artificial Organs, 24, 845-851.
doi:10.1046/j.1525-1594.2000.06618.x
|
[6]
|
Kong, D.L., Schuett, W., Dai, J., et al. (2002) Development of cellu-lose-DNA immunoadsorbent. Artificial Organs, 26, 200-208.
doi:10.1046/j.1525-1594.2002.06721.x
|
[7]
|
Zuo, X.L., Tao, L.J. and Gao, J.S. (2006) Kelley’s text- book of rheumatology. 7th Edition, People’s Medical Publishing House, Beijing, 1362-1364.
|
[8]
|
Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., McShane, D.J., Rothfield, N.F., et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism, 25, 1271-1277.
doi:10.1002/art.1780251101
|
[9]
|
Liu, X. and Wu, Y.B. (2008) The effect and safety of immunoadsorption therapy for children with severe systemic lupus erytheumtosus. Chinese Journal of Practical Pediatrics, 23,760-763.
|
[10]
|
Willeke, P., Schlüter, B., Schotte, H., et al. (2004) Increased frequency of GM-CSF secreting PBMC in cases with active systemic lupus erythematosus can be reduced by immunoadsorption. Lupus, 13, 257-262.
doi:10.1002/art.1780251101
|
[11]
|
Willeke, P., Schotte, H., Erren, M., et al. (2002) Concomitant reduction of disease activity and IL-10 secreting peripheral blood mononuclear cells during immunoadsorption in cases with active systenic lupus erythematosus. Cell and Molecular Biology, 48, 323-329.
|
[12]
|
Bosch, T. (1996) Current status in extracorporeal immunomodulation: Immune disorders. Artificial Organs, 20, 902-905. doi:10.1111/j.1525-1594.1996.tb04567.x
|